Once-weekly efanesoctocog alfa provides high sustained factor VIII activity with superior bleeding prevention as compared with prestudy factor VIII prophylaxis in previously treated patients 12 years ...
Factor VIII replacement products have improved the care of patients with hemophilia A, but the short half-life of these products affects the patients’ quality of life. The half-life of recombinant ...
If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...
Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
The National Institute for Health and Care Excellence (NICE) has published a final draft guidance recommending efanesoctocog alfa for treating and preventing bleeding episodes in people aged 2 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback